NTLA Intellia Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: NTLA
Price (delayed)
$10.86
Market cap
$1.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.68
Enterprise value
$1.11B
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
Highlights
Intellia Therapeutics's revenue has increased by 16% QoQ and by 15% YoY
The gross profit has grown by 16% from the previous quarter and by 15% YoY
The company's quick ratio fell by 26% YoY but it rose by 8% QoQ
Intellia Therapeutics's equity has decreased by 26% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of NTLA
Market
Valuations
Earnings
Shares outstanding
107.35M
Market cap
$1.17B
Enterprise value
$1.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
21.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.04
Revenue
$52.86M
Gross profit
$52.86M
Operating income
-$512.02M
Net income
-$480.19M
EBIT
-$480.19M
EBITDA
-$470.05M
Free cash flow
-$421.82M
Per share
Balance sheet
Liquidity
EPS
-$4.68
EPS diluted
-$4.68
Free cash flow per share
-$4.07
Book value per share
$6.91
Revenue per share
$0.51
TBVPS
$8.67
Total assets
$898.89M
Total liabilities
$183.64M
Debt
$102.59M
Equity
$715.26M
Working capital
$400.45M
Debt to equity
0.14
Current ratio
5.19
Quick ratio
4.93
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
-889.3%
Gross margin
100%
Net margin
-908.5%
Operating margin
-968.7%
Return on assets
-45.2%
Return on equity
-57.7%
Return on invested capital
-51%
Return on capital employed
-59.8%
Return on sales
-908.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NTLA stock price
How has the Intellia Therapeutics stock price performed over time
Intraday
1.12%
1 week
-6.22%
1 month
-5.85%
1 year
-50.11%
YTD
-6.86%
QTD
15.78%
Financial performance
How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$52.86M
Gross profit
$52.86M
Operating income
-$512.02M
Net income
-$480.19M
Gross margin
100%
Net margin
-908.5%
The company's net margin rose by 21% QoQ and by 18% YoY
Intellia Therapeutics's operating margin has increased by 18% QoQ and by 15% YoY
Intellia Therapeutics's revenue has increased by 16% QoQ and by 15% YoY
The gross profit has grown by 16% from the previous quarter and by 15% YoY
Price vs fundamentals
How does NTLA's price correlate with its fundamentals
Growth
What is Intellia Therapeutics's growth rate over time
Valuation
What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.57
P/S
21.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.04
The EPS has grown by 15% YoY and by 10% from the previous quarter
The stock's P/B is 68% below its 5-year quarterly average of 4.9 but 4% above its last 4 quarters average of 1.5
Intellia Therapeutics's equity has decreased by 26% YoY and by 8% from the previous quarter
The price to sales (P/S) is 78% lower than the 5-year quarterly average of 94.2 and 18% lower than the last 4 quarters average of 25.7
Intellia Therapeutics's revenue has increased by 16% QoQ and by 15% YoY
Efficiency
How efficient is Intellia Therapeutics business performance
The ROS has grown by 21% from the previous quarter and by 18% YoY
Intellia Therapeutics's ROE has decreased by 16% YoY
The ROA has contracted by 11% YoY but it has grown by 2.4% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 9% YoY
Dividends
What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NTLA.
Financial health
How did Intellia Therapeutics financials performed over time
NTLA's current ratio is down by 28% year-on-year but it is up by 6% since the previous quarter
The company's quick ratio fell by 26% YoY but it rose by 8% QoQ
The company's debt is 86% lower than its equity
The debt to equity has grown by 27% YoY but it has contracted by 7% from the previous quarter
Intellia Therapeutics's equity has decreased by 26% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.